Beijing Science Sun Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Biao Ma

İcra Kurulu Başkanı

CN¥568.9k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	23.3yrs
CEO sahipliği	49.5%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	6.8yrs

Son yönetim güncellemeleri

Recent updates

Investor Optimism Abounds Beijing Science Sun Pharmaceutical Co., Ltd. (SZSE:300485) But Growth Is Lacking

Oct 03

Beijing Science Sun Pharmaceutical's (SZSE:300485) Problems Go Beyond Weak Profit

Apr 16

CEO

Biao Ma (60 yo)

23.3yrs

Görev süresi

CN¥568,900

Tazminat

Mr. Biao Ma serves as Chairman of the Board of Directors and General Manager at Beijing Science Sun Pharmaceutical Co., Ltd. He has served as a Director at Beijing Science Sun Pharmaceutical Co., Ltd. sinc...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Biao Ma	Chairman & GM	23.3yrs	CN¥568.90k	49.51% CN¥ 1.9b
Li Ma	CFO, Deputy GM & Director	17.9yrs	CN¥532.20k	6.2% CN¥ 238.8m
Xue Feng Wang	Deputy GM	17.9yrs	CN¥408.60k	0.012% CN¥ 480.1k
Lina Zhao	Chairman of Supervisory Board	6.8yrs	Veri yok	Veri yok
Meng Wei Song	Supervisor	13.3yrs	Veri yok	Veri yok
Wentao Xu	Non-Independent Director	6.8yrs	CN¥60.00k	Veri yok
Changcheng Yin	Non-Independent Director	3.8yrs	CN¥60.00k	Veri yok
Ning Zhang	Supervisor	3.8yrs	Veri yok	Veri yok
Fei Wang	Independent Director	6.8yrs	CN¥60.00k	Veri yok
Yanheng Song	Independent Director	less than a year	Veri yok	Veri yok
Feng Liu	Independent Director	less than a year	Veri yok	Veri yok
Yunping Dai	Independent Director	less than a year	Veri yok	Veri yok

6.8yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300485 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.8 yıldır).

Beijing Science Sun Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Beijing Science Sun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 30, 2024

Insufficient new directors

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Executive Changes

Beijing Science Sun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 21, 2022

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Directorate Changes

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.12 loss in 3Q 2023)

Investor Optimism Abounds Beijing Science Sun Pharmaceutical Co., Ltd. (SZSE:300485) But Growth Is Lacking

Beijing Science Sun Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.52 in 2Q 2023)

Beijing Science Sun Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Dividend reduced to CN¥0.022

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024

First quarter 2024 earnings released: CN¥0.40 loss per share (vs CN¥0.002 profit in 1Q 2023)

Beijing Science Sun Pharmaceutical's (SZSE:300485) Problems Go Beyond Weak Profit

Investor sentiment deteriorates as stock falls 17%

Beijing Science Sun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 30, 2024

Full year 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.43 in FY 2022)

Beijing Science Sun Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment deteriorates as stock falls 17%

Insufficient new directors

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Executive Changes

Beijing Science Sun Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 10, 2024

Third quarter 2023 earnings released: CN¥0.12 loss per share (vs CN¥0.037 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.52 (vs CN¥0.27 in 2Q 2022)

Beijing Science Sun Pharmaceutical Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023

First quarter 2023 earnings released: EPS: CN¥0.002 (vs CN¥0.22 in 1Q 2022)

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.037 (vs CN¥0.11 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.27 (vs CN¥0.09 in 2Q 2021)

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Cash Dividend for the Fiscal Year 2021, Payable on 31 May 2022

First quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.09 in 1Q 2021)

Beijing Science Sun Pharmaceutical Co., Ltd. Approves the Profit Distribution of Final Cash Dividend for the Year 2021

Beijing Science Sun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 21, 2022

Full year 2021 earnings released: EPS: CN¥0.84 (vs CN¥0.32 in FY 2020)

Beijing Science Sun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.14 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.05 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.32 (vs CN¥0.31 in FY 2019)

New 90-day low: CN¥11.30

Full year 2020 earnings released: EPS CN¥0.31 (vs CN¥0.31 in FY 2019)

Beijing Science Sun Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Directorate Changes

New 90-day low: CN¥12.45

Investor sentiment deteriorated over the past week

New 90-day low: CN¥13.92

New 90-day low: CN¥16.02

Third quarter earnings released

Beijing Science Sun Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

New 90-day low - CN¥16.09

First half earnings released

Beijing Science Sun Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş